NCT05908773 - A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 4, 2023

Primary Completion Date

August 23, 2023

Study Completion Date

September 18, 2023

Conditions

Advanced Solid Tumor

Interventions

DRUG

TTX-MC138-NODAGA-Cu64

TTX-MC138-NODAGA-Cu64 solution was developed as a PET radiopharmaceutical to permit assessment of delivery of TMX-MC138 to metastatic lesions in subjects with solid tumors. Subjects will be administered a microdose of TTX-MC138-NODAGA-Cu64 injection administered intravenously followed by whole body PET imaging.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston